Evidence map›Paper›PMID 24161262›Full record

ArticleJournal of substance abuse treatment2014

Transitions from injecting to non-injecting drug use: potential protection against HCV infection.

Don C Des Jarlais, Courtney McKnight, Kamyar Arasteh, Jonathan Feelemyer, David C Perlman, Holly Hagan, Hannah L F Cooper

Abstract read
In one paragraph

Article in Journal of substance abuse treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Don C Des JarlaisDon C. Des Jarlais Beth Israel Medical Center, New York, NY 10038, USA. Electronic address: ddesjarlais@chpnet.org.
Courtney McKnightDon C. Des Jarlais Beth Israel Medical Center, New York, NY 10038, USA.
Kamyar ArastehDon C. Des Jarlais Beth Israel Medical Center, New York, NY 10038, USA.
Jonathan FeelemyerDon C. Des Jarlais Beth Israel Medical Center, New York, NY 10038, USA.
David C PerlmanDon C. Des Jarlais Beth Israel Medical Center, New York, NY 10038, USA.
Holly HaganNew York University College of Nursing, New York, NY 10003, USA.
Hannah L F CooperEmory University Rollins School of Public Health, Atlanta, GA 30322, USA.
Mount Sinai Beth Israel · USEmory University · USNew York University · US

Funding

Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan · 1998 to 2026
$38.9M
Risk Factors for HIV/AIDS in Drug UsersR01DA003574 · NIDA · NEW YORK UNIVERSITY · PI DES JARLAIS, DON C, MCKNIGHT, COURTNEY · 1986 to 2025
$16.2M
NIDA NIH HHS P30 DA011041NIDA NIH HHS R01 DA003574
6 · The paper itself

Abstract

Transitions from injecting to non-injecting drug use have been reported from many different areas, particularly in areas with large human immunodeficiency virus (HIV) epidemics. The extent to which such transitions actually protect against HIV and HCV has not been determined. A cross-sectional survey with HIV and hepatitis C (HCV) testing was conducted with 322 former injectors (persons who had injected illicit drugs but permanently transitioned to non-injecting use) and 801 current injectors recruited in New York City between 2007 and 2012. There were no differences in HIV prevalence, while HCV prevalence was significantly lower among former injectors compared to current injectors. Years injecting functioned as a mediating variable linking former injector status to lower HCV prevalence. Transitions have continued well beyond the reduction in the threat of AIDS to injectors in the city. New interventions to support transitions to non-injecting drug use should be developed and supported by both drug treatment and syringe exchange programs.

Indexed as

Acquired Immunodeficiency SyndromeAdultCross-Sectional StudiesFemaleHepatitis CHumansMaleMiddle AgedSubstance Abuse, IntravenousSubstance-Related DisordersTime FactorsDrug useHCVHIVInjecting drug useNon-injecting drug useSubstance abuse

Identifiers

PMID24161262
PMCPMC3947032
OpenAlexW2070543121

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.